Suzanne has served as Executive Vice President and Chief Human Resources Officer since August 2018, responsible for global people, places, community and culture strategies and execution. Suzanne is an accomplished business executive with 20+ years of experience leading, scaling and elevating the human capital practices and capabilities for companies ranging from large, public multi-nationals to early-stage, entrepreneurial enterprises. Suzanne has an extensive background and track record establishing the vision and roadmap for execution in high growth organizations, with a focus on practical solutions that can adapt as the demands of the business change and mature. Prior to Arena, Suzanne held executive management roles at several public and private technology and life science companies. Suzanne is also an adjunct professor in the School of Management at San Diego State University, where she teaches Total Rewards. Suzanne holds a B.S. in Finance from San Diego State University and a Certification in Human Resources Management from the University of California, San Diego.
Steven W. Spector, JD, has served as our Executive Vice President and General Counsel since February 2012. Mr. Spector served as our Senior Vice President and General Counsel from June 2004 to February 2012, and as our Vice President and General Counsel from October 2001 to June 2004. Mr. Spector has also served as our Secretary since November 2001. Mr. Spector is a member of the board of directors and a former President of the Association of Corporate Counsel, San Diego, and an Adjunct Professor at the University of San Diego School of Law. Prior to joining Arena, Mr. Spector was a partner with the law firm of Morgan, Lewis & Bockius LLP, where he worked from 1991 to October 2001. Mr. Spector holds a B.A. and a J.D. from the University of Pennsylvania.
Robert Lisicki has served as our Executive Vice President and Chief Commercial Officer since November 2018. Prior to joining Arena, Mr. Lisicki most recently served as General Manager, Vice President Cardio-Metabolic and Inflammation at Regeneron Pharmaceuticals, Inc. Prior to joining Regeneron, he was Senior Vice President of Sales and Marketing and Chief Customer Officer at Daiichi Sankyo, Inc. Prior to Daiichi Sankyo, Mr. Lisicki held several management positions at Amgen Inc., including Vice President and General Manager, responsible for a 700+ person sales force in the U.S. His U.S. leadership experiences included such market shaping products Enbrel and Prolia. During his tenure he also covered several ex-U.S. regions, and worked as an International Franchise Lead running the development and international strategies and business plans across Amgen’s portfolio including Nephrology, Cardiology, Bone and Oncology. Prior to joining Amgen, Mr. Lisicki held various sales and marketing positions at Johnson & Johnson Corporation. Mr. Lisicki brings over 20 years of experience in biopharmaceutical management, sales and marketing to Arena. Mr. Lisicki holds a Bachelor of Science degree in Finance and Business Administration from the State University of New York at Albany.
Kevin R. Lind has served as our Executive Vice President and Chief Financial Officer since June 2016. Previously, Mr. Lind was a Principal focused on healthcare at TPG Special Situations Partners, a global investment firm, from January 2009 to June 2016. Mr. Lind was a member of the TPG Pharma Partners effort at TPG-Axon, a global investment firm, from 2006 to 2008. He served in various capacities as a healthcare investment banker at Lehman Brothers, Inc., a former global financial services firm, from 1998 to 2002 and 2004 to 2006. Mr. Lind received a B.S. from Stanford University in Biological Sciences and an M.B.A. from UCLA Anderson School of Management.
Preston Klassen MD, MHS, has served as our Executive Vice President and Head of Research and Development since August 2019. From March 2017 to July 2019 he served as Executive Vice President, Research and Development and Chief Medical Officer. Dr. Klassen has over 20 years of experience in biopharmaceutical product development. Most recently, he was Chief Medical Officer of Laboratoris Sanifit S.L. and prior to that was Executive Vice President, Head of Global Development at Orexigen Therapeutics, Inc. Previously, Dr. Klassen held several positions of increasing responsibility at Amgen Inc., including Therapeutic Area Head for Nephrology. Prior to joining Amgen, he was a faculty member in the Division of Nephrology at Duke University Medical Center. Dr. Klassen received his medical degree from the University of Nebraska College of Medicine and completed his residency in internal medicine, fellowship in nephrology, and masters in health sciences degree at Duke University.
Dr. Chris Cabell, has served as our Senior Vice President and Chief Medical Officer since August 2019. From October 2017 to July 2019, Dr. Cabell served as Senior Vice President and Head of Clinical Development. Prior to joining Arena, Dr. Cabell spent 10 years at Quintiles Inc and QuintilesIMS in a variety of management positions including Chief Medical and Scientific Officer, Global Head of Medical and Project Management, and Global Head of Business Development. Prior to joining Quintiles, Dr. Cabell was on staff at Duke University, where he led efforts to begin two important collaborative consortia. In 1999, the International Collaboration on Endocarditis was formed and Dr. Cabell received National Institutes of Health (NIH) funding to support the novel effort to study a disease of low prevalence, but high morbidity and mortality. In addition, Dr. Cabell was one of the founding members and Co-Chairs for the Cardiac Safety Research Consortium, a partnership between academic medical centers, the Food and Drug Administration (FDA), and Industry. He is also a Fellow of the American College of Cardiology. Dr. Cabell has over 100 peer reviewed publications including in the New England Journal of Medicine, JAMA, and Annals of Internal Medicine. Board certified in both internal medicine and cardiovascular diseases, Dr. Cabell is a graduate of Pennsylvania State University and Duke University, earning both his medical degree and a Masters in Health Sciences from the latter.
Dr. Douglas A. Bakan has served as our Executive Vice President of Technical Operations since May 2018. Previously, Dr. Bakan served as Senior Vice President of Technical Operations from January 2017 to May 2018. He has extensive expertise in all aspects of pharmaceutical drug development and commercialization along with over 25-years of experience in firms ranging in size from entrepreneurial startups to established publicly traded companies. In various roles at companies including Medicis Pharmaceuticals (now Valeant Pharmaceuticals), Novalar Pharmaceuticals, Neurocrine Biosciences, Alerion Biomedical, MetaProbe LLC, Corvas International and Molecular Biosystems, Inc., Dr. Bakan has been responsible for activities including discovery research, nonclinical and clinical testing, CMC efforts for drug substance and drug product supply, quality system development, program management, regulatory submission preparation and review, intellectual property creation and prosecution, venture capital financing, technology in-licensing and out-licensing, and technical due diligence. Most recently, Dr. Bakan has provided pharmaceutical consulting services to various clients in the areas of product development, regulatory dossier preparation and technical due diligence. Dr. Bakan has been an author on more than 50 scientific publications and is an inventor on more than 35 issued or pending patents. Dr. Bakan earned his BS in Biomedical Engineering at UC San Diego, his Ph.D. in Biology from UC San Diego and completed post-doctoral research at the University of Michigan in the laboratories of Drs. Raymond Counsell and Jamey Weichert.
Vince Aurentz has served as our Executive Vice President and Chief Business Officer since August 2016. Mr. Aurentz has over 28 years of experience in the biopharmaceutical industry. Previously, he served as the Chief Business Officer of Epirus Biopharmaceuticals. Prior to that, Mr. Aurentz served as President of HemoShear Therapeutics, where he oversaw the scientific and business development efforts including collaborations with global organizations such as Pfizer, Eli Lilly, Janssen R&D and Children’s National Health System. Prior to joining HemoShear Therapeutics, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA (Merck Serono) where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments. He is a former Executive Vice President at Quintiles, Co-founder and Managing Director of a venture capital and advisory business and started his career at Andersen Consulting (now Accenture). Mr. Aurentz received a B.S. in Mathematics from Villanova University.
Amit D. Munshi has served as a member of our Board of Directors since June 2016, and as our President and Chief Executive Officer since May 2016. Continue reading